Bioptik Technology Total Liabilities
Bioptik Technology total liabilities. Based on the latest financial reports, Bioptik Technology (4161) has total liabilities worth NT$597.14 Million TWD (≈ $18.81 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 4161 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Bioptik Technology (2017–2025)
Total liabilities of Bioptik Technology from 2017 to 2025. This chart illustrates how Bioptik Technology's total liabilities have evolved over time, based on quarterly financial data.
Bioptik Technology Competitors by Total Liabilities
The table below lists competitors of Bioptik Technology ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Compal Broadband Networks Inc
TW:6674
|
Taiwan | NT$325.30 Million |
|
Creas F&C Co.Ltd
KQ:110790
|
Korea | ₩454.06 Billion |
|
Wiable Corp
KQ:065530
|
Korea | ₩66.64 Billion |
|
HYUNDAI BIOLAND Co.Ltd
KQ:052260
|
Korea | ₩27.91 Billion |
|
Prescient Therapeutics Ltd
AU:PTX
|
Australia | AU$1.51 Million |
|
Piolink Inc
KQ:170790
|
Korea | ₩15.06 Billion |
|
DYPNF Co.Ltd
KQ:104460
|
Korea | ₩80.84 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Bioptik Technology's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 4161 total asset value.
Liquidity & Leverage Metrics
Bioptik Technology Total Liabilities Ratios Explained
Bioptik Technology total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioptik Technology's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioptik Technology (2017–2025)
The table below shows the annual total liabilities of Bioptik Technology from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$597.14 Million ≈ $18.81 Million |
+2.52% |
| 2024-12-31 | NT$582.47 Million ≈ $18.35 Million |
-13.52% |
| 2023-12-31 | NT$673.56 Million ≈ $21.22 Million |
-15.53% |
| 2022-12-31 | NT$797.40 Million ≈ $25.12 Million |
-3.86% |
| 2021-12-31 | NT$829.38 Million ≈ $26.13 Million |
+12.37% |
| 2020-12-31 | NT$738.10 Million ≈ $23.25 Million |
-6.10% |
| 2019-12-31 | NT$786.05 Million ≈ $24.76 Million |
-0.76% |
| 2018-12-31 | NT$792.07 Million ≈ $24.95 Million |
+16.81% |
| 2017-12-31 | NT$678.08 Million ≈ $21.36 Million |
-- |
About Bioptik Technology
Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. The company offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch, a glucose monitoring system for dogs and cats. It also p… Read more